BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24602564)

  • 1. Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside.
    Plummer R
    Clin Oncol (R Coll Radiol); 2014 May; 26(5):250-6. PubMed ID: 24602564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
    Yap TA; Sandhu SK; Carden CP; de Bono JS
    CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PARP inhibitors: significant progress in cancer therapy].
    Dantzer F; Noel G; Schreiber V
    Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [PARP inhibitors--theoretical basis and clinical application].
    Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
    Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.
    Veuger SJ; Curtin NJ; Richardson CJ; Smith GC; Durkacz BW
    Cancer Res; 2003 Sep; 63(18):6008-15. PubMed ID: 14522929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
    Nguewa PA; Fuertes MA; Valladares B; Alonso C; Pérez JM
    Prog Biophys Mol Biol; 2005 May; 88(1):143-72. PubMed ID: 15561303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
    Pernin V; Mégnin-Chanet F; Pennaneach V; Fourquet A; Kirova Y; Hall J
    Cancer Radiother; 2014 Dec; 18(8):790-8; quiz 799-802. PubMed ID: 25441760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.
    Helleday T
    Curr Opin Oncol; 2013 Nov; 25(6):609-14. PubMed ID: 24097104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy.
    Plummer ER; Calvert H
    Clin Cancer Res; 2007 Nov; 13(21):6252-6. PubMed ID: 17975135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
    Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM; Szabó C
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
    Ratnam K; Low JA
    Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a poly(ADP-ribose) polymerase inhibitor on DNA breakage and cytotoxicity induced by hydrogen peroxide and gamma-radiation.
    Cristóvão L; Rueff J
    Teratog Carcinog Mutagen; 1996; 16(4):219-27. PubMed ID: 9381409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Poly(ADP-ribose) polymerase (PARP): physiological and pathological roles].
    Makogon NV; Aleksieieva IM
    Fiziol Zh (1994); 2012; 58(3):95-112. PubMed ID: 22946318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
    Smith LM; Willmore E; Austin CA; Curtin NJ
    Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trapping Poly(ADP-Ribose) Polymerase.
    Shen Y; Aoyagi-Scharber M; Wang B
    J Pharmacol Exp Ther; 2015 Jun; 353(3):446-57. PubMed ID: 25758918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester.
    Tentori L; Balduzzi A; Portarena I; Levati L; Vernole P; Gold B; Bonmassar E; Graziani G
    Cell Death Differ; 2001 Aug; 8(8):817-28. PubMed ID: 11526435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.